- Home
- REI vs DRUG Comparison
REI vs DRUG Comparison
Compare REI & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REI
- DRUG
- Stock Information
- Founded
- REI 2004
- DRUG 2019
- Country
- REI United States
- DRUG United States
- Employees
- REI N/A
- DRUG N/A
- Industry
- REI Oil & Gas Production
- DRUG Pharmaceuticals and Biotechnology
- Sector
- REI Energy
- DRUG Health Care
- Exchange
- REI Nasdaq
- DRUG Nasdaq
- Market Cap
- REI 171.0M
- DRUG 199.7M
- IPO Year
- REI N/A
- DRUG N/A
- Fundamental
- Price
- REI $0.93
- DRUG $41.82
- Analyst Decision
- REI
- DRUG Strong Buy
- Analyst Count
- REI 0
- DRUG 7
- Target Price
- REI N/A
- DRUG $83.25
- AVG Volume (30 Days)
- REI 3.4M
- DRUG 56.4K
- Earning Date
- REI 08-06-2025
- DRUG 08-11-2025
- Dividend Yield
- REI N/A
- DRUG N/A
- EPS Growth
- REI N/A
- DRUG N/A
- EPS
- REI 0.35
- DRUG N/A
- Revenue
- REI $318,900,835.00
- DRUG N/A
- Revenue This Year
- REI N/A
- DRUG N/A
- Revenue Next Year
- REI $9.98
- DRUG N/A
- P/E Ratio
- REI $2.70
- DRUG N/A
- Revenue Growth
- REI N/A
- DRUG N/A
- 52 Week Low
- REI $0.72
- DRUG $0.94
- 52 Week High
- REI $1.94
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- REI 70.31
- DRUG 75.46
- Support Level
- REI $0.79
- DRUG $34.19
- Resistance Level
- REI $0.84
- DRUG $44.50
- Average True Range (ATR)
- REI 0.05
- DRUG 3.26
- MACD
- REI 0.02
- DRUG 0.68
- Stochastic Oscillator
- REI 82.98
- DRUG 78.90
About REI Ring Energy Inc.
Ring Energy Inc is an independent exploration and production company based in The Woodlands, Texas and is engaged in oil and natural gas development, production, acquisition, and exploration activities currently focused in the Permian Basin of Texas. The drilling operations of the company target the oil and liquid rich producing formations in the Northwest Shelf, the Central Basin Platform and the Delaware Basin all of which are part of the Permian Basin in Texas.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.